The Biolocity team (formerly the Coulter Translational Program) was selected to join an innovation accelerator network that provides small and start-up biotechnology innovators with technical and entrepreneurial support they need to accelerate the development of products that could transform the nation’s approach to health security threats.
The Coulter Translational Fund is excited to announce its next-generation effort, Biolocity.
Biolocity stems from the expansion of a successful five year pilot in which the program awarded over $6.2 million to 40 innovative projects leading to 20 start-ups, and three products on the market. As a result of the Coulter Fund’s successful pilot and the increasing demands for translational funding and mentorship, Biolocity was created to address the need for a broader network of support for university innovators.
“Biolocity extends our successful Coulter Translational Program model to reach a larger, more diverse cohort of innovators at earlier stages of their discovery, guides them using our successful experts-in-residence process, and cultivates individualized links with the commercialization ecosystem,” said Susan Margulies, Chair of the Wallace H. Coulter Department of Biomedical Engineering.
Similar to the Coulter program, Biolocity provides university innovators with a combination of investment, resources, and guidance that early-stage medical technologies need to reach critical commercialization milestones. We utilize three collaborative methods to advance translational science to the marketplace:
- BiolocityU provides educational programming in life science commercialization, trains interns on technology assessment and commercialization strategy, and offers year-round consultations opportunities to faculty innovators.
- Biolocity Fund features a bi-annual funding cycle for patient impacting technologies from our partner institutions. Candidates participate in a rigorous application process to identify the most compelling medical technologies to receive funding and coaching.
- Biolocity Launch provides awardees with active project management and coordination with the biotech commercialization ecosystem to access resources needed to achieve translational goals.
Bringing both the experience and success of the Coulter process, Biolocity creates a multi-institutional network to support the commercialization of medical technology in the southeast. The program adds new connectivity across Atlanta, while deepening its commitment to Emory University and the Georgia Institute of Technology.
“We are grateful to the Coulter Foundation’s support our pilot and proud of our teams’ successes”, said Shawna Khouri, managing director of Biolocity. “As our program evolves and continues to grow as Biolocity, we look forward to expanding our network with new partners and adding connections within the Atlanta biotech ecosystem.”
To learn more about Biolocity’s upcoming funding cycle and educational opportunities, visit www.biolocity.org.
The Coulter Program released its first annual report in 2018 highlighting the program’s success over the past four years. The 2018 Coulter Translational Program Annual Report is available here.
Jackson Medical, a Coulter seed funded project in 2014, launched nationwide sales for their product GloShield™ in June 2018. GloShield reduces operating room fires and lowers risk of patient burns during laparoscopic procedures. To learn more about their product, visit www.jackson-medical.com.
In March 2018 three Coulter funded teams received top awards at the 12th Annual Emory Technology Transfer Celebration of Technology & Innovation. Click here to read more about their projects and awards.
- Innovation of the Year: Messenger RNA-based Biopacemaker
Hee Cheol Cho, PhD
- Start-up of the Year: EMRGE, LLC
Felmont Eaves, III, MD
- Significant Event of the Year: Sanguina – AnemoCheck 510(k) FDA Approval
Wilbur Lam, MD, PhD